Ablative Therapy for Cancer After Initial Treatment Response
Part of Cancer clinical trials.
This trial tests whether destroying remaining cancer spots with targeted ablation (surgery, radiation, or other local treatments) after your cancer has responded to initial chemotherapy or immunotherapy can help you live longer. You must have a few remaining tumors that can be treated locally.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with one of 17 specific cancer types (breast, lung, head/neck, stomach, pancreas, bladder, kidney, prostate, colon, melanoma, or others)
- Your cancer responded well to your first-line treatment (chemotherapy, immunotherapy, or targeted therapy) and has not grown for 3–6 months
- You have a small number of remaining tumor spots (oligometastatic disease) that doctors agree can be safely destroyed with local ablation
- You are in good overall health (ECOG performance status 0 or 1, meaning you can care for yourself and do light activity)
- You have not received any prior systemic cancer treatment before your current first-line therapy
- All remaining tumors are from the same original cancer (no new separate cancers)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving local treatments (like surgery or radiation) to cancer spots later—after starting immunotherapy or targeted therapy—helps people with stomach or esophageal cancer that has spread to a few places. It aims to improve outcomes by timing treatments carefully.
This study tests whether continuing your current systemic (whole-body) therapy is safe and helpful when only 1–2 metastatic spots start growing. It also checks whether adding local treatment (such as radiation or ablation) to those spots can better control the cancer.
This study is for people with solid tumors that have spread to a few spots (5 or fewer) in the body. It tests whether using a focused treatment like radiation or ablation on those spots can help control the cancer long-term.
This trial tests whether using local treatments (like targeted radiation or ablation) on a few new spots of cancer can help people whose cancer is otherwise stable on their current treatment. It enrolls people with various solid tumors, such as breast, gynecologic, head & neck, sarcoma, or other types.
This trial tests a cancer treatment that uses local therapies (like radiation or targeted heat) to destroy a small number of growing spots. It is for people with certain gastrointestinal cancers whose main treatment is working well except for a few new spots, so they can avoid switching to a different drug right away.
This trial compares giving stereotactic ablative radiotherapy as one larger treatment plan versus several smaller plans for people who have only a few cancer spots (or a few spots that are worsening). It may help control metastatic disease while aiming to protect surrounding healthy organs.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.